The main difference between these two weight loss medications is that Tirzepatide is a dual-acting drug that focuses on two different hormones whereas Semaglutide only focuses on one. Keep reading to fully understand the difference between Tirzepatide and Semaglutide.
Semaglutide: Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist. It works by mimicking the GLP-1 hormone, which increases insulin secretion, decreases glucagon release, and slows gastric emptying. This leads to reduced appetite and increased feelings of fullness, contributing to weight loss and better blood sugar control.
Tirzepatide: Tirzepatide is a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist. It activates both GIP and GLP-1 receptors, enhancing the effects seen with GLP-1 alone. This dual action results in improved insulin secretion, better glucose regulation, reduced appetite, and increased satiety, often leading to more substantial weight loss compared to GLP-1 agonists alone.
Semaglutide: Clinical trials have shown that Semaglutide is effective for weight loss and glycemic control. Patients can expect a weight reduction of around 10-15% with sustained use, with significant improvements in blood sugar levels and cardiovascular risk factors.
Tirzepatide: Studies indicate that Tirzepatide tends to produce greater weight loss compared to Semaglutide. In clinical trials, a larger proportion of patients achieved higher percentages of weight loss with Tirzepatide, such as 15-20% or more. This makes Tirzepatide particularly effective for both weight loss and diabetes management.
Semaglutide: Semaglutide is administered once weekly via subcutaneous injection. It is available in different forms, including Ozempic (for Type 2 diabetes) and Wegovy (specifically for weight loss).
Tirzepatide: Tirzepatide is also administered once weekly by subcutaneous injection. It is marketed under the brand name Mounjaro for Type 2 diabetes, with ongoing studies to expand its use for weight loss and other conditions